The Latest Breaking News from Vir Biotechnology

It's been all about the biggest of the big S&P 500 stocks all year. But now, investors are starting to look for big gains from small stocks.

A Relative Strength Rating upgrade for Vir Biotechnology shows improving technical performance.

What Defines a Value Stock?

Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $3.78.

What are Value Stocks?

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…

 

Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares jumped 82.6% to $4.71 after the company reported a year over year increase in Q4 sales results and issued Q1 sales guidance above analyst estimates.